These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 32733365)

  • 1. Retrospective Observation of Low-Dose Rituximab Treatment in Chinese Patients With Neuromyelitis Optica Spectrum Disorders in a Real-World Setting.
    Xiao H; Zeng W; Li L; Li L; Cui Y; Wang J; Ye J; Yang Q
    Front Neurol; 2020; 11():642. PubMed ID: 32733365
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    Ma J; Yu H; Wang H; Zhang X; Feng K
    J Neuroimmunol; 2022 Feb; 363():577790. PubMed ID: 34959021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders.
    Correa-Díaz EP; Torres-Herrán GE; Miño Zambrano JE; Paredes-Gonzalez V; Caiza-Zambrano FJ
    Mult Scler Relat Disord; 2021 Feb; 48():102683. PubMed ID: 33338945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder.
    Ongphichetmetha T; Jitprapaikulsan J; Siritho S; Rattanathamsakul N; Detweeratham T; Prayoonwiwat N
    Sci Rep; 2024 Feb; 14(1):3503. PubMed ID: 38347079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Long-Term Use of Low Dose Rituximab and Mycophenolate Mofetil in Chinese Patients With Neuromyelitis Optica Spectrum Disorder.
    Lin J; Xue B; Li J; Zhu R; Pan J; Chen Z; Zhang X; Li X; Xia J
    Front Neurol; 2022; 13():891064. PubMed ID: 35599732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder.
    Yang Y; Wang CJ; Wang BJ; Zeng ZL; Guo SG
    J Neurol Sci; 2018 Feb; 385():192-197. PubMed ID: 29406904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab at lower dose for neuromyelitis optica spectrum disorder: a multicenter, open-label, self-controlled, prospective follow-up study.
    Zhao D; Ren K; Lu J; Liu Z; Li Z; Wu J; Xu Z; Wu S; Lei T; Ma C; Zhao S; Bai M; Li H; Guo J
    Front Immunol; 2023; 14():1148632. PubMed ID: 37614240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A meta-analysis on efficacy and safety of rituximab for neuromyelitis optica spectrum disorders.
    Dong GY; Meng YH; Xiao XJ
    Medicine (Baltimore); 2022 Sep; 101(36):e30347. PubMed ID: 36086713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    Wang Y; Chang H; Zhang X; Yin L
    Mult Scler Relat Disord; 2021 May; 50():102843. PubMed ID: 33609924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dosage of rituximab in Chinese patients with neuromyelitis optica spectrum disorder.
    Lin J; Li X; Xue B; Tong Q; Chen Z; Zhu W; Li J; Xia J
    J Neuroimmunol; 2018 Apr; 317():1-4. PubMed ID: 29501080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective Rituximab Treatment in Patients with Neuromyelitis Optica Spectrum Disorders Compared with Azathioprine and Mycophenolate.
    Yang Y; Chen L; Wu L; Yao J; Wang N; Su X; Li D; Han L; Wu W; Huang D; Jiang T; Wang Z
    Neurol Ther; 2022 Mar; 11(1):137-149. PubMed ID: 34797551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of rituximab in neuromyelitis optica: a meta-analysis.
    Gao F; Chai B; Gu C; Wu R; Dong T; Yao Y; Zhang Y
    BMC Neurol; 2019 Mar; 19(1):36. PubMed ID: 30841862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab efficacy at different initial and maintenance doses in neuromyelitis optica spectrum disorder: Experience from a national health institute in México.
    Casallas-Vanegas A; Gomez-Figueroa E; de Saráchaga AJ; Zabala-Angeles I; García-Estrada C; Salado-Burbano JC; DiazGranados-Palacio MC; Corona-Vázquez T; de Jesús Flores-Rivera J; Rivas-Alonso V
    J Neurol Sci; 2020 Dec; 419():117204. PubMed ID: 33161302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
    Evangelopoulos ME; Andreadou E; Koutsis G; Koutoulidis V; Anagnostouli M; Katsika P; Evangelopoulos DS; Evdokimidis I; Kilidireas C
    J Neurol Sci; 2017 Jan; 372():92-96. PubMed ID: 28017256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease course, progression and activity of neuromyelitis optica (NMOSD) in patients who were treated with Rituximab, 6 and 12 months after receiving the first dose of drug, in Isfahan city.
    Ashtari F; Mehdipour R; Shaygannejad V; Mansourian M
    Mult Scler Relat Disord; 2019 Sep; 34():77-82. PubMed ID: 31233958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral CD19
    Ellrichmann G; Bolz J; Peschke M; Duscha A; Hellwig K; Lee DH; Linker RA; Gold R; Haghikia A
    J Neurol; 2019 Jan; 266(1):57-67. PubMed ID: 30377816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of modified reduced-dose rituximab in Chinese patients with neuromyelitis optica spectrum disorder: A retrospective cohort study.
    Cao S; Yu H; Tian J; Li Y; Shen Y; Ji X; Wang X; Zhou X; Gu Y; Zhu F; Duan X; Xiao X; Fang Q; Chen X; Xue Q
    J Neurol Sci; 2021 Oct; 429():117616. PubMed ID: 34450520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tailoring Rituximab According to CD27-Positive B-Cell versus CD19-Positive B-Cell Monitoring in Neuromyelitis Optica Spectrum Disorder and MOG-Associated Disease: Results from a Single-Center Study.
    Bruschi N; Malentacchi M; Malucchi S; Sperli F; Martire S; Sala A; Valentino P; Bertolotto A; Pautasso M; Capobianco MA
    Neurol Ther; 2023 Aug; 12(4):1375-1383. PubMed ID: 37166677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders.
    Novi G; Bovis F; Capobianco M; Frau J; Mataluni G; Curti E; Zuliani L; Cavalla P; Brambilla L; Annovazzi P; Repice AM; Lanzillo R; Esposito S; Benedetti L; Maietta I; Sica F; Buttari F; Malucchi S; Fenu G; Landi D; Bosa C; Realmuto S; Malentacchi M; Granella F; Signori A; Bonavita S; Uccelli A; Sormani MP;
    Mult Scler Relat Disord; 2019 Nov; 36():101430. PubMed ID: 31610404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relapses shortly after rituximab treatment in neuromyelitis optica spectrum disorder.
    Shi B; Zhao M; Qiao L; Huang F; Zhou S; Wei Y; Wang J; Wang N
    Mult Scler Relat Disord; 2021 Sep; 54():103143. PubMed ID: 34273608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.